Creative Biolabs Released Professional Carbohydrate Based Conjugation Services

SHIRLEY, NY, UNITED STATES - May 30, 2019 - Creative Biolabs, a global company pioneering new biotechnologies, released professional carbohydrate based conjugation services in order to regulate antigen interaction.

The carbohydrate moiety on an antibody is located at the hinge region of the Fc domain with a sufficient distant from the variable region. Therefore, conjugation involving carbohydrate moiety is unlikely to impair the antigen binding affinity and could potentially serves as an excellent alternative for site-specific antibody drug conjugate (ADC) generation.

“Our rich-experienced team offers our clients there elaborate strategies to target carbohydrate moiety for the conjugation of ADC payload drugs. Glycan chemical oxidation comes the first. The generated aldehydes are subsequently conjugated with hydrazide- or primary amine functionalized molecules.” A scientist from Creative Biolabs said that.

“Meanwhile, glycan enzymatic and chemo-enzymatic modification and carbohydrate moiety metabolic engineering are also available in Creative Biolabs. Carbohydrate based conjugation proves to be an efficient approach for the development of site-specific ADCs, which is suitable for the conjugation to glycosylated full length IgG without requiring antibody protein sequence modification or engineering”

Using our well-established carbohydrate-based conjugation methods, Creative Biolabs is dedicated to developing ADC custom products to fit your requirements, timeline, and R&D budget. Creative Biolabs is committed in utilizing various new technologies to provide comprehensive antibody modification and conjugation services to help our clients with various ADC development project.

About Creative Biolabs

Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, preclinical evaluations, cGMP manufacturing, to clinical trails. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world.